Ikena Oncology (NASDAQ:IKNA – Free Report) had its target price cut by HC Wainwright from $11.00 to $4.00 in a research note published on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Ikena Oncology’s Q2 2024 earnings at ($0.29) EPS, Q3 2024 earnings at […]

Related Keywords

United States , , Ikena Oncology Inc , Sg Americas Securities , Ikena Oncology Company Profile , Barclays Plc , York Mellon Corp , Ikena Oncology , Free Report , Oncology Trading Down , Get Free Report , New York Mellon Corp , Capital Management , Adage Capital Partners , Capital Partners , Ikena Oncology Daily ,